Fosamax and Osteonecrosis of the Jaw: Understanding the Biological Plausibility

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Occupational Exposure Concerns

The legacy context of general health and science information has long provided foundational knowledge on medication safety and adverse event monitoring. Within this broad framework, public health communications have historically emphasized the importance of understanding drug mechanisms and patient risk factors. This heritage established systematic approaches to pharmacovigilance, where observational data and clinical reports inform evolving safety profiles. Transitioning from this general health perspective to a more focused occupational exposure concern requires recognizing that certain medications, when used in specific populations, may present unique risk patterns. The bridge concept here involves moving from population-level health guidance toward examining how prolonged pharmaceutical exposure—particularly in clinical or manufacturing settings—could influence tissue-level responses. In mass production environments, where workers may handle or be exposed to active pharmaceutical ingredients repeatedly, the question shifts from patient-centered risk assessment to occupational exposure thresholds. This pivot acknowledges that while general health information addresses broad public safety, occupational contexts demand scrutiny of cumulative exposure pathways. The concern becomes whether repeated contact with certain compounds, even at low doses, could initiate biological processes relevant to tissue integrity. Thus, the transition from general health literacy to occupational exposure concern reframes the inquiry: from 'what does the patient need to know?' to 'what are the implications for workers with sustained contact?' This sets the stage for examining exposure scenarios without yet specifying disease mechanisms.

Bridging to Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. The biological plausibility of this association is supported by mechanistic pathways involving bisphosphonate pharmacology, jawbone-specific responses, and clinical risk factors. Fosamax works by inhibiting osteoclast-mediated bone resorption, which reduces bone turnover. While this mechanism is beneficial for increasing bone mass and reducing fracture risk in osteoporosis, it can lead to adverse effects in the jawbone. The jawbone has unique structural and metabolic properties that make it susceptible to bisphosphonate-related complications. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). This research indicates that bisphosphonate treatment, including alendronate, can alter the mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These changes may impair the jawbone's ability to remodel and repair, particularly after invasive dental procedures or local trauma.

Clinical Presentation and Risk Factors for ONJ

The clinical presentation of ONJ typically involves exposed bone in the jaw that persists for more than eight weeks, often accompanied by pain, swelling, infection, or delayed healing after tooth extraction. According to FDA-approved labeling, osteonecrosis of the jaw can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The labeling further notes that known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the Fosamax label includes a specific section on osteonecrosis of the jaw under 'Warnings and Precautions.' This section describes the condition, its association with bisphosphonate use, and known risk factors. It also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal duration of bisphosphonate therapy to minimize ONJ risk, noting only that the optimal duration of use has not been determined and that for patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation Considerations and Evidence

Causation-related considerations for affected patients involve the timeline between exposure and documented harm. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), suggesting that while ONJ is a known adverse event, its incidence in clinical trials was low and not statistically different from placebo. This highlights the challenge of establishing individual causation, as ONJ can also occur spontaneously or due to other risk factors. For patients who develop ONJ after Fosamax exposure, the biological plausibility is supported by the drug's mechanism of action and the jawbone's unique response to bisphosphonate therapy. The multiscale characterization of jawbone treated with osteoporosis therapeutic agents provides evidence that bisphosphonates alter jawbone properties in ways that may predispose to ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077). However, the presence of other risk factors, such as dental procedures or comorbidities, often complicates the attribution of causation solely to Fosamax. The label's warning that ONJ is generally associated with tooth extraction or local infection underscores the multifactorial nature of the condition. In summary, the evidence supports a biologically plausible link between Fosamax and osteonecrosis of the jaw, mediated by bisphosphonate-induced suppression of bone turnover and alterations in jawbone mechanical and mineral properties. The FDA-approved label provides warnings about this risk, including known risk factors and recommendations for dental management. The timeline of onset can vary widely, and while discontinuation of the drug may lead to symptom relief in many patients, recurrence upon rechallenge has been documented. Affected patients should be evaluated for other contributing factors, and healthcare providers should consider the balance of benefits and risks when prescribing Fosamax, particularly for long-term use.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the biological plausibility of Fosamax causing osteonecrosis of the jaw?

Fosamax (alendronate) inhibits osteoclast-mediated bone resorption, reducing bone turnover. The jawbone has unique structural and metabolic properties that make it susceptible to bisphosphonate-related complications. Multiscale characterization studies show that bisphosphonate treatment alters mechanical stability of teeth, tissue mineral density, and nanoindentation properties of the jawbone matrix, impairing its ability to remodel and repair (https://pubmed.ncbi.nlm.nih.gov/40345077).

What are the known risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

How long does it take for ONJ symptoms to appear after starting Fosamax?

The time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief after stopping the drug, but some may have recurrence if rechallenged.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.